Novo Nordisk’s oral semaglutide tablet received a positive opinion from the European Medicines Agency’s CHMP on June 5, 2026. The recommendation includes four dosage strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. This new tablet form serves the same patient population as the injectable Wegovy version.
The regulatory milestone arrived as the American Diabetes Association (ADA) Scientific Sessions began. Novo Nordisk plans to present new clinical data from its cardiometabolic portfolio during the conference.
Investors are tracking the event for updates on pipeline candidates such as CagriSema. These advancements could further solidify the company's leadership in the obesity and diabetes sectors.